All In Biotech

Drug Trial Radar · NCT01476657

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Mar 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

210

Actual

Start

Oct 2011

Primary completion

Dec 2016

Study completion Jan 2017

Sponsor

Lead sponsor
SecuraBioIndustry
Sponsor type
Industry
First posted
Nov 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.

Conditions

  • Hematologic Malignancies

Interventions

  • IPI-145 (duvelisib)Drug

    Oral Twice A Day (BID) Dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: At least 28 days (1 Cycle)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    New York, New York

  • Site not named

    Columbus, Ohio

  • Site not named

    Nashville, Tennessee

  • Site not named

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.